Annex III
United Kingdom
Part 3 of Annex VI is amended as follows:
- (1)
Table 3.1 is amended as follows:
- (a)
the entry corresponding to index number 015-188-00-X is deleted;
- (b)
the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries:
‘
006-086-00-6 fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate 276-696-7 72490-01-8 Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 1
M = 10 000
015-154-00-4 ethephon; 2-chloroethylphosphonic acid 240-718-3 16672-87-0 Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
Skin Corr. 1C
Aquatic Chronic 2
H311
H332
H302
H314
H411
GHS06
GHS05
GHS09
Dgr
H311
H332
H302
H314
H411
EUH071 015-192-00-1 tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate 432-770-2 139189-30-3 Skin Sens. 1 H317 GHS07
Wng
H317 601-023-00-4 ethylbenzene 202-849-4 100-41-4 Flam. Liq. 2
Acute Tox. 4*
STOT RE 2
Asp. Tox. 1
H225
H332
H373 (hearing organs)
H304
GHS02
GHS07
GHS08
Dgr
H225
H332
H373 (hearing organs)
H304
601-026-00-0 styrene 202-851-5 100-42-5 Flam. Liq. 3
Repr. 2
Acute Tox. 4*
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
H226
H361d
H332
H372 (hearing organs)
H315
H319
GHS02
GHS08
GHS07
Dgr
H226
H361d
H332
H372 (hearing organs)
H315
H319
* D 603-061-00-7 tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
202-625-6 97-99-4 Repr. 1B
Eye Irrit. 2
H360Df
H319
GHS08
GHS07
Dgr
H360Df
H319
605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B
Muta. 2
Acute Tox. 3*
Acute Tox. 3*
Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1
H350
H341
H301
H311
H331
H314
H317
GHS08
GHS06
GHS05
Dgr
H350
H341
H301
H311
H331
H314
H317
*
Skin Corr. 1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 5 % ≤ C < 25 %
Eye Irrit. 2; H319: 5 % ≤ C < 25 %
STOT SE 3; H335: C ≥ 5 %
Skin Sens. 1; H317: C ≥ 0,2 %
B, D 605-008-00-3 acrolein;
prop-2-enal;
acrylaldehyde
203-453-4 107-02-8 Flam. Liq. 2
Acute Tox. 1
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H225
H330
H300
H311
H314
H400
H410
GHS02
GHS06
GHS05
GHS09
Dgr
H225
H330
H300
H311
H314
H410
EUH071 Skin Corr. 1B;
H314: C ≥ 0,1 %
M = 100
M = 1
D 616-035-00-5 cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
261-043-0 57966-95-7 Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H302
H373 (blood, thymus)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361fd
H302
H373 (blood, thymus)
H317
H410
M = 1
M = 1
’
- (c)
the following entries are inserted in accordance with the order of the entries set out in Table 3.1:
‘
050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. 2
Acute Tox. 4
STOT RE 1
Skin Sens. 1A
H361d
H302
H372 (nervous system, immune system)
H317
GHS08
GHS07
Dgr
H361d
H302
H372 (nervous system, immune system)
H317
050-029-00-8 dimethyltin dichloride 212-039-2 753-73-1 Repr. 2
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
STOT RE 1
Skin Corr. 1B
H361d
H330
H301
H311
H372 (nervous system, immune system)
H314
GHS08
GHS06
GHS05
Dgr
H361d
H330
H301
H311
H372 (nervous system, immune system)
H314
EUH071 601-088-00-9 4-vinylcyclohexene 202-848-9 100-40-3 Carc. 2 H351 GHS08
Wng
H351 601-089-00-4 muscalure; cis-tricos-9-ene 248-505-7 27519-02-4 Skin Sens. 1B H317 GHS07
Wng
H317 604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. 2
Skin Irrit. 2
Eye Dam. 1
H361f
H315
H318
GHS08
GHS05
Dgr
H361f
H315
H318
604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 Lact.
Aquatic Acute 1
Aquatic Chronic 1
H362
H400
H410
GHS09
Wng
H362
H410
M = 100
M = 1 000
606-146-00-7 tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one - 87820-88-0 Carc. 2
Acute Tox. 4
Aquatic Chronic 2
H351
H302
H411
GHS08
GHS07
GHS09
Wng
H351
H302
H411
606-147-00-2 cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one 405-230-9 101205-02-1 Repr. 2 H361d GHS08
Wng
H361d 607-705-00-8 benzoic acid 200-618-2 65-85-0 STOT RE 1
Skin Irrit. 2
Eye Dam. 1
H372 (lungs) (inhalation)
H315
H318
GHS08
GHS05
Dgr
H372 (lungs) (inhalation)
H315
H318
607-706-00-3 methyl 2,5-dichlorobenzoate 220-815-7 2905-69-3 Acute Tox. 4
STOT SE 3
Aquatic Chronic 2
H302
H336
H411
GHS07
GHS09
Wng
H302
H336
H411
612-287-00-5 fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine - 79622-59-6 Repr. 2
Acute Tox. 4
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361d
H332
H318
H317
H400
H410
GHS08
GHS07
GHS05
GHS09
Dgr
H361d
H332
H318
H317
H410
M = 10
M = 10
613-317-00-X penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole 266-275-6 66246-88-6 Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361d
H302
H400
H410
GHS08
GHS07
GHS09
Wng
H361d
H302
H410
M = 1
M = 1
613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate - 473798-59-3 Aquatic Chronic 2 H411 GHS09 H411 616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 Acute Tox. 3
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H372 (larynx)
H318
H317
H400
H410
GHS06
GHS08
GHS05
GHS09
Dgr
H331
H302
H372 (larynx)
H318
H317
H410
M = 10
M = 1
’
- (a)
- (2)
Table 3.2 is amended as follows:
- (a)
the entry corresponding to index number 015-188-00-X is deleted;
- (b)
the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries:
‘
006-086-00-6 fenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate 276-696-7 72490-01-8 Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)22-36/37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
015-154-00-4 ethephon; 2-chloroethylphosphonic acid 240-718-3 16672-87-0 C; R34
Xn; R20/21/22
N; R51-53
C; N
R: 20/21/22-34-51/53
S: (1/2-)26-36/37/39-45-61
Xi; R37: 5 % ≤ C < 10 % 015-192-00-1 tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate 432-770-2 139189-30-3 R43 Xi
R: 43
S: (2-)24-37
601-023-00-4 ethylbenzene 202-849-4 100-41-4 F; R11
Xn; R20-48/20-65
F; Xn
R: 11-20-48/20-65
S: (2-)16-24/25-29-62
601-026-00-0 styrene 202-851-5 100-42-5 Repr. Cat. 3; R63
Xn; R20-48/20
Xi; R36/38
R10
Xn
R: 10-20-36/38-48/20-63
S: (2-)23-36/37-46
Xn; R20: C ≥ 12,5 %
Xi; R36/38: C ≥ 12,5 %
D 603-061-00-7 tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
202-625-6 97-99-4 Repr. Cat. 2; R61
Repr. Cat. 3; R62
Xi; R36
T
R: 36-61-62
S: 45-53
Xi; R36: C ≥ 10 % 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. Cat. 2; R45
Muta. Cat. 3; R68
T; R23/24/25
C; R34
R43
T
R: 23/24/25-34-43-45-68
S: 45-53
T; R23/24/25: C ≥ 25 %
Xn; R20/21/22: 5 % ≤ C < 25 %
C; R34: C ≥ 25 %
Xi; R36/37/38: 5 % ≤ C < 25 %
R43: C ≥ 0,2 %
B, D 616-035-00-5 cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
261-043-0 57966-95-7 Repr. Cat. 3; R62-63
Xn; R22-48/22
R43
N; R50-53
Xn; N
R: 22-43-48/22-62-63-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
’
- (c)
the following entries are inserted in accordance with the order of the entries set out in Table 3.2:
‘
050-028-00-2 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate 260-829-0 57583-35-4 Repr. Cat. 3; R63
T; R48/25
Xn; R22
R43
T
R: 22-43-48/25-63
S: (1/2-)36/37-45
050-029-00-8 dimethyltin dichloride 212-039-2 753-73-1 Repr. Cat. 3; R63
T+; R26
T; R24/25-48/25
C; R34
T+
R: 24/25-26-34-48/25-63
S: (1/2-)26-28-36/37/39-45-63
601-088-00-9 4-vinylcyclohexene 202-848-9 100-40-3 Carc. Cat. 3; R40 Xn
R: 40
S: (2-)36/37
601-089-00-4 muscalure; cis-tricos-9-ene 248-505-7 27519-02-4 R43 Xi
R: 43
S: (2-)24-37
604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. Cat. 3; R62
Xi; R38-41
Xn
R: 38-41-62
S: (2-)26-36/37/39-46
604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 R64
N; R50-53
N
R: 50/53-64
S: 60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
606-146-00-7 tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one – 87820-88-0 Carc. Cat. 3; R40
Xn; R22
N; R51-53
Xn; N
R: 22-40-51/53
S: (2-)36/37-60-61
606-147-00-2 cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one 405-230-9 101205-02-1 F; R11
Repr. Cat. 3; R63
F; Xn
R: 11-63
S: (2-)16-36/37-46
607-705-00-8 benzoic acid 200-618-2 65-85-0 T; R48/23
Xi; R38-41
T
R: 38-41-48/23
S: (1/2-)26-39-45-63
607-706-00-3 methyl 2,5-dichlorobenzoate 220-815-7 2905-69-3 Xn; R22
N; R51-53
Xn; N
R: 22-51/53
S: (2-) 46-61
612-287-00-5 fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine - 79622-59-6 Repr. Cat. 3; R63
Xn; R20
Xi; R41
R43
N; R50-53
Xn; N
R: 20-41-43-50/53-63
S: (2-)26-36/37/39-46-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
613-317-00-X penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole 266-275-6 66246-88-6 Repr. Cat. 3; R63
Xn; R22
N; R50-53
Xn; N
R: 22-50/53-63
S: (2-) 36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-318-00-5 fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate - 473798-59-3 N; R51-53 N
R: 51/53
S: 60-61
616-212-00-7 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate 259-627-5 55406-53-6 T; R23-48/23
Xn; R22
Xi; R41
R43
N; R50
T; N
R: 22-23-41-43-48/23-50
S: (1/2-)24-26-37/39-45-63
N; R50: C ≥ 2,5 % ’
- (a)